Business Description
Percheron Therapeutics Ltd
ISIN : AU0000317281
Total Employee Number:
8Compare
Compare
Traded in other countries / regions
PER.AustraliaAWY0.GermanyPERCF.USA IPO Date
2001-12-20Description
Percheron Therapeutics Ltd is a clinical-stage biotechnology company advancing first-in-class immuno-oncology therapies to tackle some of the difficult-to-treat cancers. The company's product pipeline comprises the following drug candidates: avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, and HMBD-002, a monoclonal antibody that has shown activity in a wide range of animal models of cancer and has shown evidence of synergy when combined with other immuno-oncology drugs such as Keytruda (pembrolizumab). Its operating segments are ATL1102, which generates maximum income, and HMBD-002.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 144.71 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37 | |||||
3-Year EPS without NRI Growth Rate | 38.3 | |||||
3-Year FCF Growth Rate | 16.4 | |||||
3-Year Book Growth Rate | -30.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.45 | |||||
9-Day RSI | 61.07 | |||||
14-Day RSI | 60.02 | |||||
3-1 Month Momentum % | -20 | |||||
6-1 Month Momentum % | -42.86 | |||||
12-1 Month Momentum % | -63.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.64 | |||||
Quick Ratio | 7.64 | |||||
Cash Ratio | 5.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.4 | |||||
Shareholder Yield % | -25.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -58.27 | |||||
ROA % | -50.33 | |||||
ROIC % | -234.52 | |||||
3-Year ROIIC % | 237.77 | |||||
ROC (Joel Greenblatt) % | -15406.45 | |||||
ROCE % | -58.07 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1 | |||||
Price-to-Tangible-Book | 1.67 | |||||
EV-to-EBIT | -0.75 | |||||
EV-to-EBITDA | -0.79 | |||||
EV-to-Forward-EBITDA | -0.5 | |||||
EV-to-Forward-Revenue | 4.18 | |||||
EV-to-FCF | -0.45 | |||||
Earnings Yield (Greenblatt) % | -133.33 | |||||
FCF Yield % | -105.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Percheron Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.004 | ||
| Beta | 1.2416 | ||
| 3-Year Sharpe Ratio | -0.39 | ||
| 3-Year Sortino Ratio | -0.49 | ||
| Volatility % | 63.91 | ||
| 14-Day RSI | 60.02 | ||
| 14-Day ATR (A$) | 0.000441 | ||
| 20-Day SMA (A$) | 0.00435 | ||
| 12-1 Month Momentum % | -63.64 | ||
| 52-Week Range (A$) | 0.002 - 0.011 | ||
| Shares Outstanding (Mil) | 1,522.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Percheron Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Percheron Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2013-11-06 | 0.15 (+0.00%) |
Show
Entries
Percheron Therapeutics Ltd Frequently Asked Questions
What is Percheron Therapeutics Ltd(ASX:PER)'s stock price today?
The current price of ASX:PER is A$0.01. The 52 week high of ASX:PER is A$0.01 and 52 week low is A$0.00.
When is next earnings date of Percheron Therapeutics Ltd(ASX:PER)?
The next earnings date of Percheron Therapeutics Ltd(ASX:PER) is .
Does Percheron Therapeutics Ltd(ASX:PER) pay dividends? If so, how much?
Percheron Therapeutics Ltd(ASX:PER) does not pay dividend.
Press Release
Articles on Percheron Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers